Rebecca Chambers's most recent trade in Veracyte Inc was a trade of 5,370 Common Stock done at an average price of $26.7 . Disclosure was reported to the exchange on June 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 02 Jun 2025 | 5,370 | 138,529 (0%) | 0% | 26.7 | 143,594 | Common Stock |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 30,200 | 143,899 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 23,170 | 136,680 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.84 per share. | 27 Feb 2025 | 11,911 | 124,769 (0%) | 0% | 33.8 | 403,068 | Common Stock |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.76 per share. | 27 Feb 2025 | 11,070 | 113,699 (0%) | 0% | 34.8 | 384,793 | Common Stock |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 43.85 per share. | 03 Feb 2025 | 527 | 113,510 (0%) | 0% | 43.9 | 23,109 | Common Stock |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 43.23 per share. | 02 Dec 2024 | 7,000 | 114,037 (0%) | 0% | 43.2 | 302,622 | Common Stock |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.12 per share. | 02 Dec 2024 | 3,464 | 121,037 (0%) | 0% | 44.1 | 152,832 | Common Stock |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 38.34 per share. | 12 Nov 2024 | 15,275 | 124,501 (0%) | 0% | 38.3 | 585,663 | Common Stock |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.55 per share. | 02 Sep 2024 | 3,464 | 139,776 (0%) | 0% | 31.5 | 109,289 | Common Stock |
| Inari Medical Inc | Rebecca Chambers | Director | Sale of securities on an exchange or to another person at price $ 45.99 per share. | 21 Jun 2024 | 260 | 9,684 | - | 46.0 | 11,957 | Common Stock |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.75 per share. | 02 Jun 2024 | 3,462 | 143,240 (0%) | 0% | 20.8 | 71,837 | Common Stock |
| Inari Medical Inc | Rebecca Chambers | Director | Sale of securities on an exchange or to another person at price $ 45.39 per share. | 20 May 2024 | 964 | 9,944 | - | 45.4 | 43,756 | Common Stock |
| Inari Medical Inc | Rebecca Chambers | Director | Grant, award, or other acquisition of securities at price $ 42.41 per share. | 24 Apr 2024 | 4,126 | 10,908 | - | 42.4 | 174,984 | Common Stock |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 4,318 | 148,891 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.10 per share. | 15 Mar 2024 | 2,189 | 146,702 (0%) | 0% | 21.1 | 46,188 | Common Stock |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 59,856 | 144,573 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.00 per share. | 02 Mar 2024 | 6,112 | 84,717 (0%) | 0% | 24 | 146,688 | Common Stock |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.54 per share. | 02 Dec 2023 | 1,800 | 90,829 (0%) | 0% | 26.5 | 47,772 | Common Stock |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.72 per share. | 02 Jun 2023 | 1,183 | 95,754 (0%) | 0% | 26.7 | 31,610 | Common Stock |
| Inari Medical Inc | Rebecca Chambers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 2,412 | 6,782 | - | 0 | Common Stock | |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 42,956 | 42,956 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 26,014 | 96,937 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 02 Mar 2023 | 2,726 | 70,923 (0%) | 0% | 24.1 | 65,697 | Common Stock |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.14 per share. | 02 Dec 2022 | 735 | 72,998 (0%) | 0% | 29.1 | 21,418 | Common Stock |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 02 Sep 2022 | 3,023 | 73,733 (0%) | 0% | 19.2 | 57,981 | Common Stock |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 36,496 | 36,496 | - | - | Common Stock | |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 21,404 | 76,756 (0%) | 0% | 0 | Common Stock | |
| Inari Medical Inc | Rebecca Chambers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 2,420 | 4,370 | - | 0 | Common Stock | |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 37,773 | 37,773 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 20,728 | 54,728 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2021 | 67,000 | 67,000 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2021 | 34,000 | 34,000 (0%) | 0% | 0 | Common Stock | |
| Outset Medical Inc | Rebecca Chambers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 50.72 per share. | 24 Jun 2021 | 16,727 | 13,597 | - | 50.7 | 848,373 | Common Stock |
| Outset Medical Inc | Rebecca Chambers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2021 | 16,727 | 77,745 | - | - | Non-Qualified Stock Option (right to buy) | |
| Outset Medical Inc | Rebecca Chambers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.25 per share. | 24 Jun 2021 | 16,727 | 30,324 | - | 6.3 | 104,544 | Common Stock |
| Inari Medical Inc | Rebecca Chambers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2021 | 1,950 | 1,950 | - | 0 | Common Stock | |
| Outset Medical Inc | Rebecca Chambers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.25 per share. | 25 May 2021 | 16,727 | 30,324 | - | 6.3 | 104,544 | Common Stock |
| Outset Medical Inc | Rebecca Chambers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2021 | 16,727 | 94,472 | - | - | Non-Qualified Stock Option (right to buy) | |
| Outset Medical Inc | Rebecca Chambers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 45.11 per share. | 25 May 2021 | 16,727 | 13,597 | - | 45.1 | 754,535 | Common Stock |
| Outset Medical Inc | Rebecca Chambers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Apr 2021 | 16,727 | 111,199 | - | - | Stock Option (Right to Buy) | |
| Outset Medical Inc | Rebecca Chambers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.25 per share. | 27 Apr 2021 | 16,727 | 30,324 | - | 6.3 | 104,544 | Common Stock |
| Outset Medical Inc | Rebecca Chambers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 56.33 per share. | 27 Apr 2021 | 8,499 | 21,825 | - | 56.3 | 478,756 | Common Stock |
| Outset Medical Inc | Rebecca Chambers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 56.89 per share. | 27 Apr 2021 | 8,228 | 13,597 | - | 56.9 | 468,056 | Common Stock |
| Outset Medical Inc | Rebecca Chambers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.25 per share. | 25 Mar 2021 | 16,727 | 30,324 | - | 6.3 | 104,544 | Common Stock |
| Outset Medical Inc | Rebecca Chambers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2021 | 16,727 | 127,926 | - | - | Stock Option (Right to Buy) | |
| Outset Medical Inc | Rebecca Chambers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 50.16 per share. | 25 Mar 2021 | 13,135 | 13,597 | - | 50.2 | 658,903 | Common Stock |
| Outset Medical Inc | Rebecca Chambers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.11 per share. | 25 Mar 2021 | 3,592 | 26,732 | - | 49.1 | 176,415 | Common Stock |
| Outset Medical Inc | Rebecca Chambers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 27,037 | 27,037 | - | - | Stock Option (Right to Buy) |